NeuroNOS

An Israeli pharmaceutical company developing a drug for autism.

NeuroNOS is developing a drug for autism. The development is based on scientific research and a team that includes Nobel Prize laureates. The funding will be used to advance further development, with the goal of delivering a genuine medical solution
26 Days to go

0% of funding target

$85,000

Minimum investment
Investment type:
Equity
Company Stage:
Seed
Category:
Pharma & Biopharma

Highlights

Highlights


Pitch

Pitch

Team

Team

אמיר אבניאל
Amir Avniel is a seasoned biotechnology and life sciences executive with more than 20 years of experience founding, leading, and scaling companies from early research and entrepreneurship through public-company operations. He currently serves as Chief Executive Officer of NeuroNOS, where he leads the company’s strategic, scientific, and business activities. Over the course of his career, Mr. Avniel has led the IPOs of three life-science companies—two on NASDAQ and one on the Tel Aviv Stock Exchange—and has managed public companies while working extensively with U.S. and Israeli capital markets.
פרופ‘ הייתם עמל
Prof. Haitham Amal serves as Chief Scientific Officer of NeuroNOS and is a world-leading expert in nitric oxide signaling and brain disorders. He is a Visiting Professor at Boston Children’s Hospital and Harvard Medical School and heads a translational medicine laboratory at the Hebrew University of Jerusalem, following postdoctoral training at MIT and affiliation with the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. Prof. Amal has received numerous prestigious research grants and awards, including ISF, DFG, U.S. Department of Defense funding, and the Krill Prize of the Wolf Foundation, and was the first to demonstrate a direct link between nitric oxide and autism in a landmark study published in Advanced Science.
פרופ‘ דוד גרינברג
Prof. David Greenberg is a senior physician and researcher in pediatric infectious diseases, serving as Director of the Saban Children’s Hospital and Head of the Pediatric Infectious Diseases Unit at Soroka University Medical Center, as well as Professor of Pediatrics and Infectious Diseases at Ben-Gurion University of the Negev. He is a founder and has served as Chief Medical Officer and medical advisor to Beyond Air, Beyond Cancer, and ENOX Biopharma, and holds multiple patents in the diagnosis and treatment of infectious diseases. Prof. Greenberg is a member of Israel’s National Vaccine and Infectious Disease Advisory Board, has held leadership roles in professional societies, and has authored more than 200 peer-reviewed scientific publications.
אבישי ברמן
Avishai Berman is a finance executive with experience in finance and accounting across technology and healthcare companies. He currently serves as Finance Manager at Beyond Air, where he oversees financial management and supports the company’s ongoing operations. Previously, he worked as an accounting consultant at Dell EMC and as a Controller at Novolog – The Health Care Group. He began his professional career at EY, where he was part of the high-tech audit practice.
פרופ‘ עמיחי מאירוביץ
Prof. Amichai Meirovitz is the Head of the Oncology Department at Soroka University Medical Center and a leading expert in clinical oncology. He has extensive experience in the diagnosis and treatment of cancer and combines clinical leadership with multidisciplinary patient care and research activities. Prof. Meirovitz leads Soroka’s oncology services with a focus on advanced, personalized cancer care and clinical collaboration.

Financial data

Financial data

Updates

Updates

Currently there are no updates in this pitch

The financing rounds, made through the ExitValley platform, are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) of the Israeli Securities Law - 1968.
Under this model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors, who are not qualified investors, and the round of financing is not in the format of an offering arrangement ("רכז הצעה"), as defined in the Securities Law.
Follow us